BCL2 and hematologic disorder: Furthermore, our data reveal that baseline expression of BCL‐2, BCL‐xL or MCL‐1 were not predictive of sensitivity to the BH3‐mimetics tested, similar to studies in hematological malignancies and solid tumors.13, 14